Davita Inc vs Lennar Corporation — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Lennar Corporation trades at $77.7 (market cap $18.10B). The key difference: Lennar Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.63% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Lennar Corporation for 67 Days on average.
| DVA | LEN | |
|---|---|---|
Market Cap | $11.28B | $18.10B |
Volume | 650,294 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $133.13 |
52-Week Low | $103.87 | $74.44 |
Typical Hold Time | 113 Days | 67 Days |
Enterprise Value | $24.00B | $22.52B |
Dividend Yield | — | 2.63% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Lennar (LEN) trades at $77.60, showing modest daily gains amid bearish technical signals. The stock faces fundamental pressure with declining revenue and net income margins, though valuation metrics appear attractive with P/E of 14.42 and P/B below 1. Recent Q3 2026 earnings missed expectations, while Berkshire Hathaway's accumulating stake provides institutional support. Cash flow trends show operational challenges with negative net cash flow in 2025.
Investment outlook balances value opportunity against housing sector headwinds. The stock's below-book valuation and Berkshire's backing offer potential upside, but declining profitability and elevated mortgage rates pose significant risks. Analyst consensus leans cautiously optimistic with 46% buy ratings, though technical indicators suggest near-term bearish pressure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →